Business Description
Mayinglong Pharmaceutical Group Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE000001HN2
Compare
Compare
Traded in other countries / regions
600993.China IPO Date
2004-05-17Description
Mayinglong Pharmaceutical Group Co Ltd is a China-based company mainly involved in pharmaceutical development, retailing and wholesaling. The company provides ointments, suppositories, and tablets for hemorrhoids.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.94 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | 1 | |||||
| Interest Coverage | 29.94 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 6.84 | |||||
| Beneish M-Score | -2.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9 | |||||
| 3-Year EBITDA Growth Rate | 11.6 | |||||
| 3-Year EPS without NRI Growth Rate | 9.7 | |||||
| 3-Year FCF Growth Rate | -15.9 | |||||
| 3-Year Book Growth Rate | 11 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.05 | |||||
| 9-Day RSI | 48.57 | |||||
| 14-Day RSI | 44.49 | |||||
| 6-1 Month Momentum % | -8.33 | |||||
| 12-1 Month Momentum % | 20.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.38 | |||||
| Quick Ratio | 4.94 | |||||
| Cash Ratio | 3.78 | |||||
| Days Inventory | 70.42 | |||||
| Days Sales Outstanding | 37.93 | |||||
| Days Payable | 54.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.55 | |||||
| Dividend Payout Ratio | 0.31 | |||||
| 3-Year Dividend Growth Rate | 32.6 | |||||
| Forward Dividend Yield % | 1.55 | |||||
| 5-Year Yield-on-Cost % | 2.84 | |||||
| Shareholder Yield % | -2.54 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.86 | |||||
| Operating Margin % | 14.78 | |||||
| Net Margin % | 15.05 | |||||
| ROE % | 13.99 | |||||
| ROA % | 9.99 | |||||
| ROIC % | 28.35 | |||||
| ROC (Joel Greenblatt) % | 79.14 | |||||
| ROCE % | 14.69 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 19.91 | |||||
| PE Ratio without NRI | 19.91 | |||||
| Shiller PE Ratio | 28.18 | |||||
| Price-to-Owner-Earnings | 22.7 | |||||
| PEG Ratio | 1.16 | |||||
| PS Ratio | 2.99 | |||||
| PB Ratio | 2.71 | |||||
| Price-to-Tangible-Book | 2.8 | |||||
| Price-to-Free-Cash-Flow | 35.42 | |||||
| Price-to-Operating-Cash-Flow | 24.32 | |||||
| EV-to-EBIT | 12.4 | |||||
| EV-to-EBITDA | 12.4 | |||||
| EV-to-Revenue | 2.32 | |||||
| EV-to-FCF | 27.54 | |||||
| Price-to-Projected-FCF | 1.33 | |||||
| Price-to-DCF (Earnings Based) | 1.16 | |||||
| Price-to-DCF (FCF Based) | 1.14 | |||||
| Price-to-Median-PS-Value | 0.85 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.9 | |||||
| Price-to-Graham-Number | 1.58 | |||||
| Price-to-Net-Current-Asset-Value | 3.58 | |||||
| Price-to-Net-Cash | 6.67 | |||||
| Earnings Yield (Greenblatt) % | 8.05 | |||||
| Forward Rate of Return (Yacktman) % | 23.39 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mayinglong Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,244.975 | ||
| EPS (TTM) (Â¥) | 1.13 | ||
| Beta | 1.31 | ||
| Volatility % | 37.37 | ||
| 14-Day RSI | 44.49 | ||
| 14-Day ATR (Â¥) | 0.577979 | ||
| 20-Day SMA (Â¥) | 22.2295 | ||
| 12-1 Month Momentum % | 20.57 | ||
| 52-Week Range (Â¥) | 19.54 - 32.2 | ||
| Shares Outstanding (Mil) | 431.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mayinglong Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mayinglong Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mayinglong Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993)'s stock price today?
The current price of SHSE:600993 is ¥22.56. The 52 week high of SHSE:600993 is ¥32.20 and 52 week low is ¥19.54.
When is next earnings date of Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993)?
The next earnings date of Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993) is .
Does Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993) pay dividends? If so, how much?
The Dividend Yield %  of Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993) is 1.55% (As of Today), Highest Dividend Payout Ratio of Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993) was 0.56. The lowest was 0.08. And the median was 0.28. The  Forward Dividend Yield % of Mayinglong Pharmaceutical Group Co Ltd(SHSE:600993) is 1.55%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers